{"name":"Repligen Corporation","slug":"repligen","ticker":"RGEN","exchange":"NASDAQ","domain":"repligen.com","description":"Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ","hq":"Waltham, MA","founded":0,"employees":"2000","ceo":"Tony Hunt","sector":"Bioprocessing / Life Science Tools","stockPrice":102.4,"stockChange":-4.63,"stockChangePercent":-4.33,"marketCap":"$5.8B","metrics":{"revenue":763339008,"revenueGrowth":14.8,"grossMargin":53.1,"rdSpend":54177000,"netIncome":48894000,"cash":566021000,"dividendYield":0,"peRatio":112.5,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"XEMBIFY patent cliff ($20.0M at risk)","drug":"XEMBIFY","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"Repligen Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Repligen reported fourth quarter and full year 2023 financial results, with revenue of $143.8 million and $533.8 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-09-14","type":"deal","headline":"Repligen to Acquire BioXcellence","summary":"Repligen announced the acquisition of BioXcellence, a bioprocessing company, for $175 million.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxQdGczYXZ1Rzh1SGk0Mjc2NmlrY0FXdEsyOURfdzgxakhxT29nZWk2akhQQjNUWW5fMVM3WENaR1NKeHFleVVocElVeG13Z3BYcHhGWC1kTVk0bTVnXzdxWW1fdHBjaVhnMFlaZF8yZWFicW9PdUU4U25GdG9Seml1eTRreUIyMGlPbmpOZUpMdnRYUjk4cTFfY1RNNkluaWdUblBDRXkzbWdNOHdvUjBucWdLbGZNZUd3cU9qVi11cEw2WllXMzFvZVN0THJ3cjAxT2RJRFRIblNFcmFCMUJRR1BWckdTYWdjTlJ1ZzB6MTJZWnVBMkFwN0h4UDFhV3c3WG1MQWpkbVZGRUZ2NEYzaA?oc=5","date":"2026-03-06","type":"pipeline","source":"StockStory","summary":"AMN Healthcare Services, RadNet, Evolent Health, Repligen, and Amphastar Pharmaceuticals Stocks Trade Down, What You Need To Know - StockStory","headline":"AMN Healthcare Services, RadNet, Evolent Health, Repligen, and Amphastar Pharmaceuticals Stocks Trade Down, What You Nee","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPWExaN2I1VzJXWGI5U2g1eXpoOGdUZjVCWEw3N0FOM1I2c0U3a1J3TXVBWGdkakI0MTFfQjhrYlpjdUNGWUIxMlBTdHo3SXNoQkFnTTRERGdhY0RpRk5uV3NBODZGQVVlTGVPSlhlZmF6OTZRSjZFaGtRM19tNFFVYnRNeEh4aVJUUkRZZXhCZDVYMUlSdTk4R3pNcw?oc=5","date":"2026-02-22","type":"earnings","source":"Finviz","summary":"Repligen (RGEN) To Report Earnings Tomorrow: Here Is What To Expect - Finviz","headline":"Repligen (RGEN) To Report Earnings Tomorrow: Here Is What To Expect","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPY3BYdXZOZWk0SjIzWUZIWFQ2TXlOQ3dPamNRcHBfZnBscFZObXY2b1RCVDluMGVhS3YwVHk5RldselJLaExra2V4ejRnY3ZyMHFlOFphbC02YkxDMjZsaXUtSmhPN3hWMTNHMWtUVWdkMDlwQlVlenhMVm1Nb085Zm93WVNYdFZqMVRXcThpZ1JUY3NHNjBYWEtvSEU4X1BBZ0RVUzh1QkdJdFFITExKSElFTDVmZw?oc=5","date":"2026-02-16","type":"pipeline","source":"Kalkine Media","summary":"Repligen (NASDAQ:RGEN) Growth Sensitivity Mirrors Nasdaq Composite Moves - Kalkine Media","headline":"Repligen (NASDAQ:RGEN) Growth Sensitivity Mirrors Nasdaq Composite Moves","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxPb0xSQmhjd293a3JLem9seUgwdTYtdzNmM2ZrVUJSLVRKTG9fYXZvdi1CTW5FY1REbFFVRXR5dnp3dEx1bDRsVEt5NWpIWlVlZXl3WlBkTTdacUtPdHlBeHpnR05FQkw0WEFwZVFOaEVhRkxKUmpTRUlDZDJuck9SZXNlYUdGSlJORHZaQ0lzMkFIZ0tnWmp4aXZfeGlhVHQwM2pnY2F1Y1NCa08wekp3MW1nV3ZfM2c0LXoxNzJsdktRaWdqZS0wamp6QzB6MUM0bW1HeExuemZtR1JYdGhSR3kxaDVYdTVkdXh0UndrMngwd1VQb05wTUg4SXFoNXhrQVZ2Wg?oc=5","date":"2026-01-30","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on These Healthcare Stocks: Repligen (RGEN), Definium Therapeutics (DFTX) - The Globe and Mail","headline":"Analysts Are Bullish on These Healthcare Stocks: Repligen (RGEN), Definium Therapeutics (DFTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOejI2ZElzQUctQ2YxWEJPNXRkaURtVHFNeGRyMy00VzkwUDMyUl9lMS0taFJ4UjFBQXFKTVl3dk9xT1BDX2RWOXJvQTZhdGZlWVRlTGZzOWR5U0hsdEM0Sk80QnhieUpyaHd4UHJCUmpic25MVFJEWnJRdEU2S2cyWFAyVkVRQmppdlpkUl90dWNHS0NjejVzUURqdGtVR2RXWk9kRXZjLUs?oc=5","date":"2025-11-14","type":"pipeline","source":"Seeking Alpha","summary":"Repligen Stock: Rare Growth In The Biopharma Supplies Industry (NASDAQ:RGEN) - Seeking Alpha","headline":"Repligen Stock: Rare Growth In The Biopharma Supplies Industry (NASDAQ:RGEN)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-12","type":"earnings","source":"simplywall.st","summary":"Repligen's (NASDAQ:RGEN) Earnings May Just Be The Starting Point - simplywall.st","headline":"Repligen's (NASDAQ:RGEN) Earnings May Just Be The Starting Point","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOZVgyS2xtQU5fTmpMTm9qc1ZvYzFJZUFxckZvZHhiTm1NSzNhRjBOQ3NET1RncnZEOEE2eXlNQ0RNeFVmYXRCRHo2VXpRY1VWTjZTaWVpQU1NX2NGc1VSZ0c3Tl9qZHNFb3hOcFkxMHF6Q2Z0aGxsVjdKZDlzb28xZTY5M1VXTmN2dHV3Y0NBSWV2ZC1tS0ZjYl9UaVhfWkNhWlNfWXFUeU8?oc=5","date":"2025-10-26","type":"earnings","source":"TradingView","summary":"Repligen Earnings: What To Look For From RGEN - TradingView","headline":"Repligen Earnings: What To Look For From RGEN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPV1N4NDJxNVp4bl9Mc2plS21tdjJIYnBaV01IeG1KQkNCamdtbkxPeExpWlJnVVpqd3lTX1pZRGpzalJETGtENUdKSFMzVE5MMmpRSG5fOFFFdVdQeUtuUXowbGpvb3lNWWtpZDVxbmdzVGd3dE9YQ21xNk43dTE5RWlpRHFVb2I2?oc=5","date":"2025-10-09","type":"deal","source":"Yahoo Finance","summary":"Is Repligen (RGEN) The Best Healthcare Stock to Buy Now? - Yahoo Finance","headline":"Is Repligen (RGEN) The Best Healthcare Stock to Buy Now?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-04","type":"pipeline","source":"simplywall.st","summary":"Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) 28% Share Price Surge - simplywall.st","headline":"Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) 28% Share Price Surge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxQQ1ZCYWxSUUx0a01PR3BQXzk5UnM0VlNPblpFai1YUXlpSUtEUVdEaGlDWDctLVp6MWJ6WmJPYVkzVlZhOUlyendzN21Mc2hJX1BEVGVoZVhIOXNkaHB1c2lQc2xMaXR3VURVSU1LTVRFelJ1VDBmTjNyQ1loS3BFODY5Uy1qZW9oVVRwYmdFWWk4ZDVCMzF1QVN5djBETDQtY0xhcV9IZGFKZ0U0dER1ZDdFVkYya3RkaThIOHpjbGxkcnVkOC1xS2M1VFMzT2d4SGl6bHQ3RGFLa0lLaUg1dUowVXZNYkl0aGVBeGxrRWdGSnhNdVhpOVZlX0psUQ?oc=5","date":"2025-09-30","type":"pipeline","source":"TradingView","summary":"Repligen, BrightSpring Health Services, Danaher, Thermo Fisher, and Amgen Shares Skyrocket, What You Need To Know - TradingView","headline":"Repligen, BrightSpring Health Services, Danaher, Thermo Fisher, and Amgen Shares Skyrocket, What You Need To Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBEd3k3QkpONUlUS1dVc2ZNcFljWGRzQ1lCeVZRWUNrQVVTSmoybmZLU1h5UUs1WDQybDBJRzVkelR4T3V2MDhIM3ZhQ0p0NFp6?oc=5","date":"2023-11-17","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPLUhJeXJack4zcGRBWkNuN05YSE9Hb2cxMmFMNzJRdXFIdk8tTE9xVldkdlVYUFVYMFBEbFhJVjEzNHRWR3N6SjVVZ0dxdGtMdGV1aU9NZGNsamQ5QkRRcGtsX2J4Mk9yWEswcnBaV2c5aWw3eFRCRm1uaTZKMTlSOFNJbjhYYnBQaXB1TEpfSkFLRFNWUFE?oc=5","date":"2022-03-02","type":"pipeline","source":"citybiz","summary":"908 Devices Appoints Tony Hunt to Board of Directors - citybiz","headline":"908 Devices Appoints Tony Hunt to Board of Directors","sentiment":"neutral"}],"patents":[{"drugName":"XEMBIFY","drugSlug":"sucrose-octasulfate","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":20000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Sartorius","GE Healthcare","Danaher"],"therapeuticFocus":["Biologics","Bioprocessing"],"financials":{"source":"sec_edgar+yahoo","revenue":141236000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":141236000,"period":"2017-12-31"},{"value":36580000,"period":"2017-09-30"},{"value":32455000,"period":"2017-06-30"},{"value":30590000,"period":"2017-03-31"},{"value":104541000,"period":"2016-12-31"},{"value":24677000,"period":"2016-09-30"}],"grossProfit":60485000,"grossProfitHistory":[{"period":"2025-12-31","value":386245000},{"period":"2024-12-31","value":274645000},{"period":"2023-12-31","value":278440000},{"period":"2022-12-31","value":455706000}],"rdSpend":54177000,"rdSpendHistory":[{"period":"2025-12-31","value":54177000},{"period":"2024-12-31","value":43200000},{"period":"2023-12-31","value":42722000},{"period":"2022-12-31","value":43936000}],"sgaSpend":290508000,"operatingIncome":41560000,"operatingIncomeHistory":[{"period":"2025-12-31","value":41560000},{"period":"2024-12-31","value":-31923000},{"period":"2023-12-31","value":17134000},{"period":"2022-12-31","value":195941000}],"netIncome":48894000,"netIncomeHistory":[{"period":"2025-12-31","value":48894000},{"period":"2024-12-31","value":-25514000},{"period":"2023-12-31","value":35596000},{"period":"2022-12-31","value":185959000}],"eps":0.86,"epsHistory":[{"period":"2025-12-31","value":0.86},{"period":"2024-12-31","value":-0.46},{"period":"2023-12-31","value":0.74},{"period":"2022-12-31","value":3.24}],"cash":566021000,"cashHistory":[{"period":"2025-12-31","value":566021000},{"period":"2024-12-31","value":757355000},{"period":"2023-12-31","value":751323000},{"period":"2022-12-31","value":523458000}],"totalAssets":2949699000,"totalLiabilities":843570000,"totalDebt":689948000,"equity":2106129000,"operatingCashflow":117417000,"operatingCashflowHistory":[{"period":"2025-12-31","value":117417000},{"period":"2024-12-31","value":175394000},{"period":"2023-12-31","value":113918000},{"period":"2022-12-31","value":172083000}],"capex":-25730000,"capexHistory":[{"period":"2025-12-31","value":-25730000},{"period":"2024-12-31","value":-32905000},{"period":"2023-12-31","value":-38988000},{"period":"2022-12-31","value":-133346000}],"freeCashflow":91687000,"dividendsPaid":null,"buybacks":0,"employees":2000,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":null,"ebitda":null,"period":"2026-03-31","revenue":null,"epsBasic":0.15,"netIncome":null,"rdExpense":null,"epsDiluted":0.15,"grossProfit":null,"operatingIncome":null},{"sga":74363000,"ebit":24608000,"ebitda":49200000,"period":"2025-12-31","revenue":197913000,"epsBasic":0.24,"netIncome":13287000,"rdExpense":13120000,"epsDiluted":0.23,"grossProfit":103831000,"operatingIncome":16348000},{"sga":73663000,"ebit":22526000,"ebitda":46936000,"period":"2025-09-30","revenue":188805000,"epsBasic":0.27,"netIncome":14911000,"rdExpense":14175000,"epsDiluted":0.26,"grossProfit":100515000,"operatingIncome":12677000},{"sga":71227000,"ebit":23569000,"ebitda":48335000,"period":"2025-06-30","revenue":182366000,"epsBasic":0.26,"netIncome":14866000,"rdExpense":13958000,"epsDiluted":0.26,"grossProfit":91142000,"operatingIncome":5957000},{"sga":71255000,"ebit":13193000,"ebitda":36381000,"period":"2025-03-31","revenue":169172000,"epsBasic":0.1,"netIncome":5830000,"rdExpense":12924000,"epsDiluted":0.1,"grossProfit":90757000,"operatingIncome":6578000},{"sga":60474000,"ebit":-33146000,"ebitda":2110000,"period":"2024-12-31","revenue":167547000,"epsBasic":null,"netIncome":-33869000,"rdExpense":11677000,"epsDiluted":null,"grossProfit":38841000,"operatingIncome":-33310000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":102.4,"previousClose":107.03,"fiftyTwoWeekHigh":175.77,"fiftyTwoWeekLow":102.28,"fiftyTwoWeekRange":"102.275 - 175.77","fiftyDayAverage":119.7,"twoHundredDayAverage":138.08,"beta":1.09,"enterpriseValue":5940409344,"forwardPE":40.1,"priceToBook":2.74,"priceToSales":7.57,"enterpriseToRevenue":7.78,"enterpriseToEbitda":44.25,"pegRatio":1.95,"ebitda":134236992,"ebitdaMargin":17.6,"freeCashflow":68723376,"operatingCashflow":130707000,"totalDebt":687619968,"debtToEquity":32.7,"currentRatio":9.2,"returnOnAssets":1.2,"returnOnEquity":2.5,"analystRating":"1.5 - Buy","recommendationKey":"buy","numberOfAnalysts":18,"targetMeanPrice":179.78,"targetHighPrice":220,"targetLowPrice":142,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":5.2,"institutionHeldPercent":115.6,"sharesOutstanding":56407740,"floatShares":53369055,"sharesShort":5501852,"shortRatio":5.69,"shortPercentOfFloat":9.8,"epsTrailing":0.91,"epsForward":2.55,"revenuePerShare":13.56,"bookValue":37.33,"officers":[{"age":55,"name":"Mr. Olivier  Loeillot","title":"President, CEO & Director"},{"age":51,"name":"Mr. Jason K. Garland","title":"CFO & Chief Compliance Officer"},{"age":61,"name":"Mr. James R. Bylund","title":"Chief Operating Officer"},{"age":61,"name":"Mr. Anthony J. Hunt","title":"Advisor"},{"age":67,"name":"Mr. Ralf  Kuriyel","title":"Senior Vice President of Research & Development"},{"age":50,"name":"Mr. Brian  Douglass","title":"Senior VP & Chief Product Officer"},{"age":52,"name":"Ms. Violetta  Hughes","title":"Chief Accounting Officer"},{"age":null,"name":"Mr. Michael  Martino","title":"Chief Information Officer"}],"industry":"Medical Instruments & Supplies","irWebsite":"http://www.repligen.com/investor-relations/shareholder-center","website":"https://www.repligen.com","phone":"781 250 0111"}}